iDose® *TR*
(travoprost intracameral implant) 75 mcg

QUICK REFERENCE

Billing & Coding Guide

BILLING AND REIMBURSEMENT

Billing & Coding Guide

iDose® TR (travoprost intracameral implant) 75 mcg

HCPCS Code

Each iDose TR implant is 75 micrograms and should be billed as 75 units using J7355.

HCPCS CODE	DESCRIPTION	BILLING UNITS	PLACE OF SERVICE
J7355	Injection, travoprost, intracameral implant, 1 microgram	75	ASC or HOPD

National Drug Code

Payers often require inclusion of the drug's NDC on the claim

- While the FDA provides NDCs as 10-digit codes, some payers may require an 11-digit format
- Converting the 10-digit NDC to an 11-digit NDC may be as simple as the payer requiring you to add a leading zero
- Contact each payer for specific requirements, as they vary by payer

	FDA-SPECIFIED 10-DIGIT NDC (5-3-2 FORMAT)[1]	11-DIGIT NDC (5-4-2 FORMAT)[1]
iDose TR	25357-100-01	25357-0100-01

Drug Administration Code

CPT® code for iDose TR procedure:

CPT CODE	DESCRIPTION
0660T	Implantation of anterior segment intraocular nonbiodegradable drug-eluting system, internal approach

Modifiers

Modifiers are 2-digit codes that are added to a CPT or HCPCS code and used to provide additional information about an item or service provided*

MODIFIER	DESCRIPTION
RT	Right side (used to identify procedures performed on the right side of the body)
LT	Left side (used to identify procedures performed on the left side of the body)
JZ	For single-dose containers where there are no discarded amounts**

*Noridian Healthcare Solutions. Modifiers. Accessed May 11, 2024. https://med. noridianmedicare.com/web/jeb/topics/modifiers.)Effective July 1, 2023, Medicare requires the JZ modifier on all claims for single-dose containers where there are no discarded amounts.
**Centers for Medicare & Medicare Services. Billing and coding: JW and JZ modifier billing guidelines . Revised May 21, 2024. Accessed May 11, 2024. www.cms.gov/medicarecoverage-database/view/article.aspx?articleid=55932.)

iDose® TR
(travoprost intracameral implant) 75 mcg

Diagnosis Codes

ICD-10-CM CODE	DESCRIPTION
Open-angle glaucoma	
H40.10X0	Unspecified open-angle glaucoma
H40.111X	Primary open-angle glaucoma, right eye
H40.112X	Primary open-angle glaucoma, left eye
H40.113X	Primary open-angle glaucoma, bilateral
H40.131X	Pigmentary glaucoma, right eye
H40.132X	Pigmentary glaucoma, left eye
H40.133X	Pigmentary glaucoma, bilateral
H40.141X	Capsular glaucoma with pseudoexfoliation of lens, right eye
H40.142X	Capsular glaucoma with pseudoexfoliation of lens, left eye
H40.143X	Capsular glaucoma with pseudoexfoliation of lens, bilateral
H40.149X	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye
Ocular hypertension	
H40.051X	Ocular hypertension, right eye
H40.052X	Ocular hypertension, left eye
H40.053X	Ocular hypertension, bilateral

ICD-10CM = International Classification of Diseases, Tenth Revision, Clinical Modification.

For open-angle glaucoma codes, please add the appropriate seventh character to reflect the stage of the patient's condition:
0 = stage unspecified 1 = mild stage 2 = moderate stage 3 = severe stage 4 = indeterminate stage
Please consult the ICD-10 Codebook for more information.

INDICATIONS AND USAGE
iDose TR (travoprost intracameral implant) is indicated for the reduction of intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension (OHT).

IMPORTANT SAFETY INFORMATION

Dosage and Administration
For ophthalmic intracameral administration. The intracameral administration should be carried out under standard aseptic conditions.

Contraindications
iDose TR is contraindicated in patients with active or suspected ocular or periocular infections, patients with corneal endothelial cell dystrophy (e.g., Fuch's Dystrophy, corneal guttatae), patients with prior corneal transplantation, or endothelial cell transplants (e.g., Descemet's Stripping Automated Endothelial Keratoplasty [DSAEK]), patients with hypersensitivity to travoprost or to any other components of the product.

Warnings and Precautions
iDose TR should be used with caution in patients with narrow angles or other angle abnormalities. Monitor patients routinely to confirm the location of the iDose TR at the site of administration. Increased pigmentation of the iris can occur. Iris pigmentation is likely to be permanent.

Adverse Reactions
In controlled studies, the most common ocular adverse reactions reported in 2% to 6% of patients were increases in intraocular pressure, iritis, dry eye, visual field defects, eye pain, ocular hyperaemia, and reduced visual acuity.

Please See Full Prescribing Information.
You are encouraged to report all side effects to the FDA.
Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You may also call Glaukos at 1-888-404-1644.

For more information: 800-GLAUKOS (452-8567) idoseTRhcp.com